ArticleScientific reports2025
Inhibition activity of Artemisia vulgaris L. on Bhas 42 cell transformation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unregulated use ofThe Libyan journal of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Several factors can contribute to cancer development. Various methods are in use for cancer treatment, although their complications can be a cause of concern. Artemisia vulgaris L. is a medicinal herb proposed for treating several diseases, including cancer. This study investigated the inhibition activity of A. vulgaris on Bhas 42, a cell used to evaluate the carcinogenic potential of chemicals due to its ability to recapitulate to some extent of the multi-stage cell transformation process. Ethanolic extract of A. vulgaris was used to examine cytotoxicity and transformation inhibition activity on Bhas 42. Bhas 42 cells were induced by a cancer stimulator, 3-methylcholanthrene (MCA) or cancer promotor, 12-O-tetradecanoylphorbol-13-acetate (TPA), with and without A.vulgaris at various concentrations and date of addition. A. vulgaris can inhibit Bhas 42 cell transformation due to its smaller proportion of the transformed cells than those treated with only MCA or TPA. The most effective transformed foci inhibition condition was selected for proteomic assay. The proteomic study results also showed that the proteins related to the regulation of cancer cells, such as cancer development, proliferation, migration, transformation, and invasion of A. vulgaris treated groups, were dysregulated. Studies on the effects of A. vulgaris extract showed its ability to inhibit the transformation to cancer cells. However, further studies are required to understand these mechanisms better.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.